Xiao Yingming, Zhong Lei, Liu Jinpeng, Chen Li, Wu Yi, Li Ge
Department of Urology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China.
Emergency Department, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China.
J Pharm Anal. 2024 Dec;14(12):100964. doi: 10.1016/j.jpha.2024.100964. Epub 2024 Mar 12.
Urinary system tumors include malignancies of the bladder, kidney, and prostate, and present considerable challenges in diagnosis and treatment. The conventional therapeutic approaches against urinary tumors are limited by the lack of targeted drug delivery and significant adverse effects, thereby necessitating novel solutions. Intelligent nanomedicine has emerged as a promising therapeutic alternative for cancer in recent years, and uses nanoscale materials to overcome the inherent biological barriers of tumors, and enhance diagnostic and therapeutic accuracy. In this review, we have explored the recent advances and applications of intelligent nanomedicine for the diagnosis, imaging, and treatment of urinary tumors. The principles of nanomedicine design pertaining to drug encapsulation, targeting and controlled release have been discussed, with emphasis on the strategies for overcoming renal clearance and tumor heterogeneity. Furthermore, the therapeutic applications of intelligent nanomedicine, its advantages over traditional chemotherapy, and the challenges currently facing clinical translation of nanomedicine, such as safety, regulation and scalability, have also been reviewed. Finally, we have assessed the potential of intelligent nanomedicine in the management of urinary system tumors, emphasizing emerging trends such as personalized nanomedicine and combination therapies. This comprehensive review underscores the substantial contributions of nanomedicine to the field of oncology and offers a promising outlook for more effective and precise treatment strategies for urinary system tumors.
泌尿系统肿瘤包括膀胱、肾脏和前列腺的恶性肿瘤，在诊断和治疗方面面临着巨大挑战。传统的泌尿系统肿瘤治疗方法受到缺乏靶向药物递送和显著副作用的限制，因此需要新的解决方案。近年来，智能纳米药物已成为一种有前景的癌症治疗替代方案，它利用纳米级材料克服肿瘤固有的生物屏障，并提高诊断和治疗的准确性。在这篇综述中，我们探讨了智能纳米药物在泌尿系统肿瘤诊断、成像和治疗方面的最新进展及应用。讨论了与药物封装、靶向和控释相关的纳米药物设计原理，重点介绍了克服肾脏清除和肿瘤异质性的策略。此外，还综述了智能纳米药物的治疗应用、其相对于传统化疗的优势以及纳米药物临床转化目前面临的挑战，如安全性、监管和可扩展性。最后，我们评估了智能纳米药物在泌尿系统肿瘤管理中的潜力，强调了个性化纳米药物和联合疗法等新兴趋势。这篇全面的综述强调了纳米药物对肿瘤学领域的重大贡献，并为泌尿系统肿瘤更有效、精确的治疗策略提供了广阔前景。
